The Suzanne Somers Vanity Calamity, part 5: Conclusion

Suzanne Somers is driven by a colossal vanity.

I know this because she's trying so hard to prove it. In the process of pitching every anti-aging protocol she can get her hands on, she has become a most public and embarrassing casualty of the image-conscious MTV age. That she's so willing and anxious to push these unproven protocols on her readers and on the viewers of shows from Oprah to Good Morning America makes Somers and her desperate vanity a growing public health calamity.

What's troubling is her willingness, as a celebrity, to endorse products—in this case, protocols to treat life-threatening diseases such as cancer—without having tried them herself. She might have more real-world credibility if she undertook even one of these anti-cancer treatments and, Thighmaster-style, showcased its efficacy.

My guess is, she's betting she'll never have to.

In his best-selling book How We Die Sherwin Nuland notes, tongue in cheek, that because death certificates require a specified cause of death, "it is illegal to die of old age." Somers seems to be taking Nuland at his word, adopting the following operational syllogism that underlies all her commercial ventures:

"It is illegal to die of old age.
I will never grow old.
Therefore I will never die."

In 2005, Somers' one-woman Broadway show "The Blonde in the Thunderbird" was a barefaced decree that she wasn't—that she couldn't possibly be—as old as the calendar claims she was. When it met with negative reviews and was cancelled after a week, Somers had the gall to compare the experience of earning poor reviews to the mortifying indignities endured by prisoners at Abu Ghraib in Iraq.

That is epic vanity. And she flings it without restraint; for when cancer patients begin to flock to her list of quacks for treatment and the treatments fail, will Somers be held accountable?

Nope. And that turns her enormous vanity into something far less personal, far more dangerous; a collective public calamity.

Link to Part 1
Link to Part 2
Link to Part 3
Link to Part 4

Blog Category: 

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap